...
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer
【24h】

Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer

机译:厄洛替尼诱导的表皮生长因子受体突变的非小细胞肺癌自噬

获取原文
获取原文并翻译 | 示例

摘要

Purpose: Erlotinib is a commonly used tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC). Autophagy is a catabolic process in response to stress and deprivation of nutrients. This study aims to investigate whether autophagy confers acquired resistance to erlotinib treatment in NSCLC. Methods: Four NSCLC cell lines (HCC827, HCC4006, H358 and H1975) with different epidermal growth factor receptor (EGFR) mutation status (exon 19 deletion, exon 19 deletion, wild-type and L858R/T790M respectively) were selected. MTT assay, crystal violet staining and Annexin-V assay were performed to determine cell viability and apoptosis. Autophagic proteins were detected by Western blot. Acidic vesicular organelle (AVO) formation was determined by acridine orange staining. Autophagy inhibitor (chloroquine) and RNA interference were used to demonstrate the biological effect of erlotinib-induced autophagy. Results: In line with EGFR mutation status, it was shown that both HCC827 and HCC4006 cells were sensitive to erlotinib, while H358 and H1975 cell lines were resistant. Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression. Addition of chloroquine, as an autophagy inhibitor, enhanced erlotinib sensitivity in sensitive cells. Similarly, silencing of Atg5 or Beclin-1 significantly increased sensitivity to erlotinib in both sensitive cell lines. In contrast, there was no induction of autophagy in resistant H358 and H1975 cell lines upon erlotinib exposure. Conclusions: Erlotinib can induce both apoptosis and autophagy in sensitive NSCLC cell lines with activating EGFR mutation (exon 19 del). Inhibition of autophagy can further enhance sensitivity to erlotinib in EGFR-mutated NSCLC, suggesting that autophagy may serve as a protective mechanism.
机译:目的:厄洛替尼是非小细胞肺癌(NSCLC)中常用的酪氨酸激酶抑制剂(TKI)。自噬是对压力和营养缺乏的分解代谢过程。这项研究旨在调查自噬是否赋予NSCLC厄洛替尼治疗抗性。方法:选择四种具有不同表皮生长因子受体(EGFR)突变状态(分别为外显子19缺失,外显子19缺失,野生型和L858R / T790M)的NSCLC细胞系(HCC827,HCC4006,H358和H1975)。进行MTT测定,结晶紫染色和膜联蛋白-V测定以确定细胞活力和凋亡。通过Western印迹检测自噬蛋白。通过a啶橙染色确定酸性水泡细胞器(AVO)的形成。自噬抑制剂(氯喹)和RNA干扰被用来证明厄洛替尼诱导的自噬的生物学作用。结果:与EGFR突变状态一致,表明HCC827和HCC4006细胞均对厄洛替尼敏感,而H358和H1975细胞系具有耐药性。临床上相关浓度的厄洛替尼治疗通过p53核易位,AMPK激活和mTOR抑制在敏感的NSCLC细胞系中诱导自噬(LC3II表达增加,Atg-5 / Atg12缀合,AVO和p62降解的形成)。添加氯喹作为自噬抑制剂可增强敏感细胞中的厄洛替尼敏感性。同样,在两种敏感细胞系中,Atg5或Beclin-1的沉默也显着提高了对厄洛替尼的敏感性。相反,厄洛替尼暴露后在抗性H358和H1975细胞系中没有诱导自噬。结论:厄洛替尼可诱导具有活化EGFR突变(外显子19 del)的敏感NSCLC细胞凋亡和自噬。自噬的抑制作用可进一步增强EGFR突变的NSCLC对厄洛替尼的敏感性,表明自噬可能是一种保护机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号